By Benjamin Horney ( November 30, 2016, 4:16 PM EST) -- Swiss biotech Actelion has rejected a takeover offer lodged by U.S. health care giant Johnson & Johnson, according to a Wednesday report from StreetInsider.com. The report, which was picked up by major outlets including Reuters, said that Actelion has outright rejected Johnson & Johnson's most recent offer. Rumors that Johnson & Johnson had made an upsized bid valued at more than 25.5 billion Swiss francs ($25.15 billion) popped up earlier this week, after previous reports had said Actelion rejected an initial offer. The companies confirmed last week that they had held talks about a potential transaction....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.